Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation
NCT06778863 · View on ClinicalTrials.gov ↗
Study Summary
Phase 1 dose escalation and expansion study of CLSP-1025, a first-in-class HLA-A\*02:01 specific T cell engager (TCE) targeting solid tumors that harbor the p53 R175H mutation.
Conditions Studied
Interventions
- DRUG CLSP-1025
Study Locations (20)
California
- USC - Norris Comprehensive Cancer Center — Los Angeles
- University of California Davis Comprehensive Cancer Center — Sacramento
- University of California San Francisco — San Francisco
Texas
- Mary Crowley Cancer Research — Dallas
- Baylor University Medical Center — Dallas
- MD Anderson Cancer Center — Houston
Arizona
- HonorHealth Research Institute — Scottsdale
- The University of Arizona Cancer Center — Tucson
New York
- NYU Langone Health — New York
- Memorial Sloan Kettering Cancer Center — New York
Pennsylvania
- Thomas Jefferson University, Sidney Kimmel Cancer Center — Philadelphia
- Fox Chase Cancer Center — Philadelphia
Tennessee
- Sarah Cannon Research Institute (SCRI) Oncology Partners — Nashville
- Vanderbilt University Medical Center — Nashville
Florida
- University of Miami - Sylvester Comprehensive Cancer Center — Miami
Illinois
- The University of Chicago Comprehensive Cancer Center — Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 90 participants |
| Start Date | 2025-02-28 |
| Est. Completion | 2028-06 |
| Phase | Phase 1 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06778863
The ClinicalTrials.gov registry entry for NCT06778863 describes a study currently listed as recruiting. It is categorized as Phase 1, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 90 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Clasp Therapeutics, which has 1 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 10 conditions, with Breast Cancer appearing as the primary indexed condition, and to 1 intervention — of which CLSP-1025 is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT06778863 reports 20 study locations spanning 12 distinct geographic areas — top geographies include California, Texas, Arizona. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT06778863 about?
NCT06778863 is a clinical study titled "A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation". Phase 1 dose escalation and expansion study of CLSP-1025, a first-in-class HLA-A\*02:01 specific T cell engager (TCE) targeting solid tumors that harbor the p53 R175H mutation.
What is the current status of trial NCT06778863?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 90 participants. The study started on 2025-02-28. Estimated completion is 2028-06.
What conditions does trial NCT06778863 study?
This clinical trial studies the following conditions: Breast Cancer, Prostate Cancer, Lung Cancer, Ovarian Cancer, Advanced Solid Tumor. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT06778863?
The interventions under investigation include: CLSP-1025 (DRUG). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT06778863?
This trial is sponsored by Clasp Therapeutics, which has 1 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT06778863 being conducted?
This trial has 20 study locations across Arizona, California, Florida, Illinois, Kentucky. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.